FDA approved isavuconazole

On March 6, 2014 the FDA approved isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis.
Here you can find the FDA press release

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm437106.htm

While the aspergillosis indication is based on a large, well-designed randomized clinical trial, the mucormycosis indication is based single arm study results compared to literature data and a comparison with results from the ECMM FungiScope registry. For ECMM this is a unprecedented success in this area.

Oliver A. Cornely
President of the ECMM